U.S. markets closed

Profound Medical Corp. (PROF)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
20.19+0.07 (+0.35%)
At close: 4:00PM EDT

Profound Medical Corp.

2400 Skymark Avenue
Unit 6
Mississauga, ON L4W 5K5
647 476 1350

IndustryMedical Devices
Full Time Employees109

Key Executives

NameTitlePayExercisedYear Born
Dr. Arun Swarup MenawatChairman & CEO1.39MN/A1955
Mr. Aaron Davidson M.B.A., MBACFO & Sr. VP of Corp. Devel.233.22kN/A1968
Dr. Mathieu BurtnykVice-Pres of Clinical Affairs166.57kN/AN/A
Mr. Stephen KilmerInvestor RelationsN/AN/AN/A
Mr. Jacques F. CornetVP of Marketing & Bus. Devel.N/AN/A1956
Mr. Michael MydraVP & Head of Global Market AccessN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

Corporate Governance

Profound Medical Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.